Viridian Therapeutics, Inc. (NASDAQ: VRDN)
$20.8400
+0.6400 ( -0.24% ) 491.0K
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.
Market Data
Open
$20.8400
Previous close
$20.2000
Volume
491.0K
Market cap
$1.66B
Day range
$20.2000 - $22.0550
52 week range
$11.4000 - $27.2000
SEC Filings
| Form Type | Description | Pages | Date |
|---|---|---|---|
| 10-q | Quarterly Reports | 73 | Nov 12, 2024 |
| 8-k | 8K-related | 59 | Nov 12, 2024 |
| 4 | Insider transactions | 2 | Sep 30, 2024 |
| 4 | Insider transactions | 2 | Sep 30, 2024 |
| 4 | Insider transactions | 1 | Sep 17, 2024 |
| 8-k | 8K-related | 16 | Sep 12, 2024 |
| 8-k | 8K-related | 16 | Sep 10, 2024 |
| 10-q | Quarterly Reports | 71 | Aug 08, 2024 |
| 8-k | 8K-related | 16 | Aug 08, 2024 |
| 8-k | 8K-related | 48 | Jul 15, 2024 |